GraniteShares Advisors LLC Sells 294 Shares of Danaher Co. (NYSE:DHR)

GraniteShares Advisors LLC lessened its position in Danaher Co. (NYSE:DHR) by 4.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,977 shares of the conglomerate’s stock after selling 294 shares during the period. GraniteShares Advisors LLC’s holdings in Danaher were worth $1,383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Moneta Group Investment Advisors LLC boosted its holdings in shares of Danaher by 96,490.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock worth $6,180,839,000 after buying an additional 23,262,904 shares during the period. Norges Bank bought a new stake in shares of Danaher during the 4th quarter worth about $2,057,164,000. Wellington Management Group LLP boosted its holdings in shares of Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares during the period. Allen Investment Management LLC boosted its holdings in shares of Danaher by 1,440.7% during the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after buying an additional 1,028,976 shares during the period. Finally, J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Danaher during the 3rd quarter worth about $178,850,000. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.3 %

NYSE DHR traded up $0.69 during trading on Tuesday, hitting $240.35. The company had a trading volume of 3,225,223 shares, compared to its average volume of 2,703,507. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company has a market cap of $177.99 billion, a price-to-earnings ratio of 37.51, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The company’s fifty day moving average is $249.58 and its 200-day moving average is $229.84.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. The business had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.87 EPS. On average, sell-side analysts predict that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio is 16.90%.

Insider Buying and Selling at Danaher

In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the sale, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,957 shares of company stock worth $8,265,802. Company insiders own 10.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on DHR shares. JPMorgan Chase & Co. boosted their price objective on shares of Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, December 20th. Raymond James upped their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. KeyCorp upped their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Royal Bank of Canada upped their price objective on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, HSBC began coverage on shares of Danaher in a report on Monday, December 18th. They issued a “hold” rating for the company. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.43.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.